What Lotrel Treats: Main Uses and Benefits

Lotrel is commonly used for managing elevated systemic blood pressure (hypertension) in adults. This medication is applied in conditions where the patient experiences heightened physiological stress related to persistently high blood pressure readings. The primary therapeutic support contributes to easing the symptoms related to organ-specific functional stress by assisting with sustained management of blood pressure readings. The combination is relevant when symptoms that create noticeable physiological strain require additional symptomatic support, such as in cases of Stage 2 hypertension.

The therapeutic role supports the long-term management of systemic imbalance, providing supportive relief when symptoms that interfere with daily functioning are present. The fixed-dose combination generally assists with maintaining functional stability, which can support sustained management for patients experiencing conditions where functional stability becomes affected.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance
Primary Indication: Commonly used for hypertension, especially when dual support is needed.
Therapeutic Role: Supports management of symptoms related to systemic imbalance and heightened physiological activity.
Patient Benefit: Assists with long-term management and contributes to easing the overall symptom load.	"

Regulatory References

1. DailyMed official label

Eligibility Map: Who Can and Cannot Use Lotrel — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

• Adults with hypertension, including those who failed to achieve blood pressure control on monotherapy with either amlodipine or benazepril.

Populations for whom use is contraindicated:	Absolute Contraindication
Patients with a known hypersensitivity to amlodipine, benazepril, or any other ACE inhibitor.
Patients with a history of angioedema (swelling of the face, throat, or tongue), related or unrelated to previous ACE inhibitor use.
Pregnant patients during the second and third trimesters, due to the risk of fetal injury and death.
Patients with diabetes who are concomitantly taking the drug aliskiren.
Patients taking a neprilysin inhibitor (e.g., sacubitril), or within 36 hours of switching from one.

Age and Condition-Specific Restrictions:

• Pediatric Patients: Use is not recommended in patients under 18 years of age because safety and effectiveness have not been established.
• Severe Renal Impairment: Use is not recommended in patients with severe renal disease (creatinine clearance le 30 mL/min).
• Impaired Hepatic Function: Use requires caution.
• Lactation: Use in nursing mothers is generally not recommended as components of the medicine are excreted into human milk.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use the medicine by establishing absolute prohibitions, primarily related to the ACE inhibitor component (Benazepril), such as a history of angioedema or pregnancy beyond the first trimester. Use is further restricted based on age, organ function (renal/hepatic), and specific drug-disease interactions, such as concomitant use with aliskiren in patients with diabetes.

Lotrel Interactions with other medicines and products

This section outlines interactions with Lotrel (amlodipine besylate and benazepril hydrochloride) as formally documented in government regulatory sources, based on the actions of the ACE inhibitor and Calcium Channel Blocker components.

Official Contraindicated Combinations

The co-administration of Lotrel with Neprilysin Inhibitors (such as sacubitril) is a formally contraindicated combination due to the increased risk of angioedema. A mandatory 36-hour separation is required when switching between these medications. Additionally, combining Lotrel with Aliskiren is contraindicated in patients with diabetes or renal impairment (GFR less than 60 mL/ min) due to heightened risks of hyperkalemia, hypotension, and renal impairment.

Pharmacodynamic and Metabolic Interactions

Interacting Substance/Class	Regulatory Outcome/Restriction
Potassium Supplements / Potassium-Sparing Diuretics	Increased risk of hyperkalemia (high serum potassium levels) due to the Benazepril component.
Strong CYP3A4 Inhibitors (e.g., ketoconazole)	Increased systemic exposure of the Amlodipine component, a pharmacokinetic effect.
Simvastatin	Amlodipine increases Simvastatin exposure; the Simvastatin dose is officially restricted to 20 mg daily.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	May cause a loss of antihypertensive effect and increase the risk of renal dysfunction.
Lithium	Benazepril reduces lithium clearance, leading to elevated serum lithium levels and toxicity risk.

These official interaction statements from regulatory documents define constraints for co-administration, requiring timing separation for certain combinations and dose limitations for others.

How Lotrel Works

Lotrel is a combination medication containing amlodipine and benazepril, which act through two distinct pharmacodynamic mechanisms to modulate vascular tone.

Amlodipine Mechanism

Amlodipine, a dihydropyridine calcium channel blocker, binds to the L-type calcium channels on vascular smooth muscle cell membranes. This interaction inhibits the transmembrane influx of extracellular calcium ions. The resulting reduction in intracellular calcium concentration prevents the smooth muscle cell contraction cycle, causing vasodilation.

Benazepril Mechanism

Benazepril functions as a competitive inhibitor of the enzyme Angiotensin-Converting Enzyme (ACE). By blocking ACE, benazepril prevents the conversion of Angiotensin I to the peptide Angiotensin II. This inhibition reduces Angiotensin II-mediated vasoconstriction and also reduces the enzymatic degradation of the vasodilator peptide bradykinin.

This combined inhibition of vasoconstriction and promotion of vasodilation acts at the system level to lower peripheral vascular resistance and reduce cardiac afterload.

Lotrel is administered exclusively through the oral route as a fixed-dose combination capsule. The medication is intended for long-term maintenance therapy and is prescribed for administration once daily, a frequency pattern established to sustain consistent blood pressure control over a 24-hour period. Dosing is based on available capsule strengths, which range from a starting dose of 2.5 mg amlodipine and 10 mg benazepril (2.5/10 mg) up to the maximum recommended strength of 10 mg amlodipine and 40 mg benazepril (10/40 mg).

Administration may occur without regard to meals, as the absorption of the active components is not significantly influenced by food intake. Following initiation of therapy, the dose must not be adjusted immediately; a minimum period of approximately two weeks is required to fully assess the antihypertensive response before any upward titration is considered.

Specific procedural rules are outlined for therapy initiation in certain populations. For both older adults (aged 75 years and above) and individuals with hepatic impairment, the recommended initial dose is the lowest strength capsule (2.5 mg/10 mg). Furthermore, the drug is not recommended for individuals with severe renal impairment, specifically those with a creatinine clearance of 30 mL/minute or less. Prior to the first administration, a mandatory procedural step requires that any existing volume and/or salt depletion be corrected.

Research evidence / Overview of Studies for Lotrel (Amlodipine/Benazepril)

The clinical evaluation of the amlodipine/benazepril combination is based on studies that fall into two main categories: trials exploring short-term changes in blood pressure readings and large, long-term trials examining cardiovascular outcomes.

---

Evidence for Controlling High Blood Pressure

This section will summarize the structure of the clinical trials, including the randomized controlled studies that investigated the patterns of blood pressure change associated with the combination compared to single-drug treatments and placebo, as reported in regulatory documents.

Researchers primarily conducted randomized controlled trials (RCTs) over short time frames, typically 6 to 12 weeks, to explore how blood pressure readings changed in adults with uncomplicated high blood pressure. Studies reported measurements where the combination was associated with a greater difference in blood pressure readings across various doses when compared to placebo. Research provides context that the blood pressure patterns measured were observed across the 24-hour dosing interval.

What remains uncertain is the long-term clinical significance of these short-term differences in blood pressure readings, as initial pivotal trials focused mainly on these surrogate endpoints. Furthermore, limited insight is available on the variability of response among specific younger age groups or in patients with less common forms of high blood pressure.

---

Evidence for Long-Term Cardiovascular Outcomes

This area focuses on the design and scope of the large-scale, long-term studies, such as the ACCOMPLISH trial, which examined the frequency of major cardiovascular outcomes in high-risk patients over several years.

A major, long-term study (the ACCOMPLISH trial) was conducted to examine the combination and its association with outcomes related to physiological strain or stress over several years. The trial was designed as a head-to-head comparison, exploring the combination against an alternative, standard dual-therapy regimen (benazepril plus a diuretic). Findings described patterns where the amlodipine/benazepril combination was associated with a numerical difference in the frequency of the composite primary endpoint compared to the alternative dual-therapy regimen.

---

Consistency and Current Research Gaps

The evidence body includes observed patterns related to short-term blood pressure changes and long-term outcomes in high-risk groups.

However, several research limitation frames apply to the overall evidence. Comparative evidence is lacking for how the combination performs against placebo over long-term cardiovascular outcomes. The cardiovascular event findings reflect the specific conditions under which they were conducted, specifically a comparison against one alternative dual-therapy combination in a high-risk population, and do not provide insight into a comparison against no treatment.

Common questions about Lotrel (FAQ)

Q: How quickly does Lotrel start to work after the first dose?

According to the official product information, studies showed that the medication began lowering blood pressure within about one hour after the first dose was taken. The largest reduction in blood pressure typically occurs between two and eight hours after administration. However, the full, sustained blood pressure lowering effect is usually established after approximately two weeks of regular use.

---

Q: Does Lotrel affect heart rate?

Official postmarketing reports have included effects on heart rhythm. These reports list the potential occurrence of arrhythmia (an irregular heart rhythm) and a fast or irregular heartbeat among the possibilities. This information is based on patient experiences reported to regulatory bodies after the medication was approved.

---

Q: What happens if I miss a dose of Lotrel?

The official patient information describes a procedure where, if a dose is missed, it can be taken as soon as it is remembered. However, if it is more than 12 hours after the usual time, the procedure is to skip the missed dose completely and take the next dose at the regularly scheduled time.

---

Q: What should be done if someone feels faint or very dizzy while taking Lotrel?

Regulatory documents describe a procedure where a person who feels dizzy or faint may be advised to lie down to help prevent falls or injury. The guidance further suggests sitting for a few moments before standing to help prevent dizziness from returning. This symptom, which can be related to very low blood pressure (hypotension), is most likely to occur in people whose body is low on salt or fluid.

---

Q: Does Lotrel cause weight gain or weight loss?

Postmarketing reports submitted to regulatory bodies have included changes in body weight. This means that both weight decrease and weight gain have been listed as possible effects for some patients. This information reflects data collected during post-approval surveillance.

---

Q: Can Lotrel cause flushing or a feeling of warmth in the face and neck?

Official reports indicate that flushing is a less common side effect. This is described as a reddening of the face, neck, arms, and occasionally the upper chest, sometimes accompanied by a feeling of warmth.

---

Q: What is the reason for the different milligram combinations available for Lotrel?

The different milligram combinations are available to provide healthcare providers with options for dose adjustment. Clinical trials showed that increasing the dose of either the amlodipine or benazepril component resulted in greater blood pressure lowering. The aim is to provide options for therapeutic adjustment based on patient need.

---

Q: Can Lotrel affect blood sugar levels?

Postmarketing safety reports have included the occurrence of hyperglycemia, which refers to high blood sugar. Additionally, official regulatory warnings highlight the use of the drug in people who have diabetes when taken with a specific interacting medication (aliskiren).

---

Q: Does Lotrel cause problems with sleeping or drowsiness?

Official reports of less common side effects have included sleepiness (or somnolence). This information is based on data collected during clinical trials and post-approval surveillance.

---

Q: Can Lotrel cause symptoms like confusion or nervousness?

Regulatory documents list both confusion and nervousness among the less common side effects reported by patients. These reports help define the full scope of potential effects, though they occur infrequently.

---

Q: What is the concern about Lotrel in patients with certain heart valve conditions?

Official warnings state that patients with severe aortic stenosis may be at risk of symptomatic hypotension. Symptomatic hypotension is defined as very low blood pressure that results in symptoms. Severe aortic stenosis is a condition where the aortic valve is narrowed.

---

Q: What should a person do before any surgery, including dental work, while taking Lotrel?

Official patient information states that a person should inform any doctors or dentists that they are taking Lotrel if they are scheduled to have surgery. This precaution also applies if a person is preparing to get allergy shots, such as those for bee stings.

---

Q: Is there any information about how Lotrel affects sexual function?

Postmarketing reports have included some effects on sexual function. These reports mention the possibility of erectile dysfunction (impotence) and a decrease in interest in sexual intercourse.

How to Store and Dispose of Lotrel?

Lotrel (amlodipine besylate and benazepril hydrochloride) capsules must be stored according to regulatory standards to ensure stability and safety.

Required Storage Conditions

Requirement	Details
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Container	Keep in the original container, tightly closed.
Protection	Store in a dry place and protect from excessive moisture.

Child Safety and Disposal

All medication must be stored out of the sight and reach of children. Unused or expired Lotrel must be disposed of according to local regulations, often utilizing authorized drug take-back programs. Official guidance prohibits flushing this medication down the toilet unless specifically instructed.